What is Actinium Pharmac's earnings per share (EPS)?

Actinium Pharmac (ATNM) reported diluted earnings per share of $-1.09 for fiscal year 2025. This represents a 14.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Actinium Pharmac Financials

ATNM

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Actinium Pharmac (ATNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 25 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.73x

For every $1 of reported earnings, Actinium Pharmac generates $0.73 in operating cash flow (-$24.6M OCF vs -$33.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$90K

Actinium Pharmac generated $90K in revenue in fiscal year 2025.

EBITDA

-$36.1M

YoY+14.0%

Actinium Pharmac's EBITDA was -$36.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.0% from the prior year.

Net Income

-$33.9M

YoY+11.4%

Actinium Pharmac reported -$33.9M in net income in fiscal year 2025. This represents an increase of 11.4% from the prior year.

EPS (Diluted)

$-1.09

YoY+14.2%

Actinium Pharmac earned $-1.09 per diluted share (EPS) in fiscal year 2025. This represents an increase of 14.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$24.7M

YoY+25.4%

Actinium Pharmac generated -$24.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 25.4% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

31M

YoY+0.6%

5Y CAGR+12.3%

Actinium Pharmac had 31M shares outstanding in fiscal year 2025. This represents an increase of 0.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-40274.4%

Actinium Pharmac's operating margin was -40274.4% in fiscal year 2025, reflecting core business profitability.

Net Margin

-37652.2%

Actinium Pharmac's net profit margin was -37652.2% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

N/A

Capital Allocation

R&D Spending

$21.1M

YoY-29.7%

5Y CAGR+5.6%

10Y CAGR+4.6%

Actinium Pharmac invested $21.1M in research and development in fiscal year 2025. This represents a decrease of 29.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$104K

YoY+845.5%

5Y CAGR-16.3%

10Y CAGR+8.1%

Actinium Pharmac invested $104K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 845.5% from the prior year.

ATNM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$90K	N/A	$81K-92.1%	$1.0M-10.0%	$1.1M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$900K	N/A
Gross Profit	N/A	N/A	N/A	N/A	$244K	N/A
R&D Expenses	$21.1M-29.7%	$30.0M-22.3%	$38.7M+67.1%	$23.1M+28.3%	$18.0M+12.1%	$16.1M
SG&A Expenses	$15.2M+26.0%	$12.1M-9.4%	$13.3M+11.1%	$12.0M+48.6%	$8.1M+28.0%	$6.3M
Operating Income	-$36.2M+13.9%	-$42.1M+18.9%	-$51.9M-52.2%	-$34.1M-36.6%	-$25.0M-11.5%	-$22.4M
Interest Expense	N/A	N/A	$3.1M+185.4%	$1.1M+472.1%	$190K+6.7%	$178K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$33.9M+11.4%	-$38.2M+21.7%	-$48.8M-47.9%	-$33.0M-33.3%	-$24.8M-11.5%	-$22.2M
EPS (Diluted)	$-1.09+14.2%	$-1.27+30.6%	$-1.83-33.6%	$-1.37-14.2%	$-1.20	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$90K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.2M-12.9%	$4.9M-36.6%	$7.7M	N/A	$9.8M+10.8%	$8.8M+33.0%	$6.6M	N/A
SG&A Expenses	$1.5M-41.5%	$2.6M-70.6%	$8.9M	N/A	$2.8M-21.3%	$3.6M+21.3%	$3.0M	N/A
Operating Income	-$5.7M+24.1%	-$7.5M+54.9%	-$16.6M	N/A	-$12.6M-1.5%	-$12.4M-29.4%	-$9.6M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$927K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.1M+25.4%	-$6.9M+56.8%	-$15.9M	N/A	-$11.6M-1.9%	-$11.4M-30.9%	-$8.7M	N/A
EPS (Diluted)	$-0.16+27.3%	$-0.22+56.9%	$-0.51	N/A	$-0.37+2.6%	$-0.38-22.6%	$-0.31	N/A

ATNM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$76.9M-5.6%	$81.4M-28.7%	$114.2M+42.1%	$80.4M+21.1%	$66.4M
Current Assets	N/A	$74.5M-4.8%	$78.3M-29.5%	$110.9M+39.1%	$79.7M+22.8%	$64.9M
Cash & Equivalents	N/A	$72.9M-4.9%	$76.7M-29.6%	$108.9M+39.9%	$77.8M+22.4%	$63.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$44.1M-2.1%	$45.1M-5.5%	$47.7M+597.2%	$6.8M+34.8%	$5.1M
Current Liabilities	N/A	$8.1M-4.1%	$8.5M-20.1%	$10.6M+55.4%	$6.8M+43.5%	$4.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$32.8M-10.0%	$36.4M-45.3%	$66.5M-9.6%	$73.5M+19.9%	$61.3M
Retained Earnings	N/A	-$375.8M-11.3%	-$337.6M-16.9%	-$288.8M-12.9%	-$255.7M-10.7%	-$231.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$56.2M-10.9%	$63.0M-8.2%	$68.6M-10.7%	$76.9M-6.4%	$82.1M-8.6%	$89.9M+1.7%	$88.4M+8.5%	$81.4M
Current Assets	$54.4M-10.9%	$61.0M-8.2%	$66.5M-10.8%	$74.5M-6.3%	$79.5M-8.7%	$87.1M+2.0%	$85.4M+9.1%	$78.3M
Cash & Equivalents	$53.4M-10.9%	$59.9M-8.3%	$65.3M-10.4%	$72.9M-7.3%	$78.7M-8.6%	$86.0M+2.4%	$84.1M+9.6%	$76.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$42.4M-3.7%	$44.0M+2.4%	$43.0M-2.7%	$44.1M+0.5%	$43.9M-4.6%	$46.0M+3.4%	$44.5M-1.3%	$45.1M
Current Liabilities	$6.8M-17.8%	$8.3M+16.9%	$7.1M-12.7%	$8.1M+5.1%	$7.8M-20.3%	$9.7M+20.6%	$8.1M-5.1%	$8.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$13.8M-27.5%	$19.0M-26.0%	$25.7M-21.6%	$32.8M-14.3%	$38.2M-12.8%	$43.8M-0.1%	$43.9M+20.6%	$36.4M
Retained Earnings	-$403.8M-1.3%	-$398.6M-1.8%	-$391.8M-4.2%	-$375.8M-1.8%	-$369.2M-3.2%	-$357.6M-3.3%	-$346.3M-2.6%	-$337.6M

ATNM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$24.6M+25.7%	-$33.1M+30.1%	-$47.3M-647.6%	$8.6M+141.4%	-$20.9M+3.5%	-$21.6M
Capital Expenditures	$104K+845.5%	$11K-92.8%	$153K-58.2%	$366K+175.2%	$133K-47.4%	$253K
Free Cash Flow	-$24.7M+25.4%	-$33.1M+30.3%	-$47.5M-673.7%	$8.3M+139.4%	-$21.0M+4.0%	-$21.9M
Investing Cash Flow	-$104K-845.5%	-$11K+92.8%	-$153K+58.2%	-$366K-175.2%	-$133K+47.4%	-$253K
Financing Cash Flow	-$217K-100.7%	$29.3M+97.2%	$14.9M-35.7%	$23.1M-34.4%	$35.2M-53.8%	$76.2M
Dividends Paid	N/A	N/A	N/A	$0	$0	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.3M-17.3%	-$5.4M+28.8%	-$7.6M-31.7%	-$5.8M+52.0%	-$12.0M-50.2%	-$8.0M-8.1%	-$7.4M+1.5%	-$7.5M
Capital Expenditures	N/A	N/A	N/A	$0	$0	$0-100.0%	$11K	$0
Free Cash Flow	N/A	N/A	N/A	-$5.8M+52.0%	-$12.0M-50.2%	-$8.0M-7.9%	-$7.4M+1.4%	-$7.5M
Investing Cash Flow	N/A	N/A	N/A	$0	$0	$0+100.0%	-$11K	$0
Financing Cash Flow	-$209K-6866.7%	-$3K-50.0%	-$2K+33.3%	-$3K-100.1%	$4.6M-53.8%	$10.0M-32.6%	$14.8M+1138.9%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATNM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	21.3%	N/A
Operating Margin	-40274.4%	N/A	-64098.8%-60787.7pp	-3311.1%-1128.9pp	-2182.2%	N/A
Net Margin	-37652.2%	N/A	-60269.1%-57063.6pp	-3205.5%-1040.0pp	-2165.6%	N/A
Return on Equity	N/A	-116.7%+17.5pp	-134.2%-84.5pp	-49.7%-16.0pp	-33.7%+2.5pp	-36.2%
Return on Assets	N/A	-49.7%+10.2pp	-59.9%-31.0pp	-28.9%+1.9pp	-30.8%+2.6pp	-33.5%
Current Ratio	N/A	9.14-0.1	9.21-1.2	10.44-1.2	11.66-2.0	13.62
Debt-to-Equity	N/A	1.35+0.1	1.24+0.5	0.72+0.6	0.09+0.0	0.08
FCF Margin	-27426.7%	N/A	-58627.2%-59430.8pp	803.7%+2639.3pp	-1835.6%	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-6324.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-5701.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-37.2%-1.0pp	-36.2%+25.8pp	-62.0%	N/A	-30.3%-4.4pp	-25.9%-6.1pp	-19.8%	N/A
Return on Assets	-9.1%+1.8pp	-10.9%+12.3pp	-23.2%	N/A	-14.1%-1.5pp	-12.6%-2.8pp	-9.8%	N/A
Current Ratio	7.96+0.6	7.34-2.0	9.35+0.2	9.14-1.1	10.25+1.3	8.95-1.6	10.59+1.4	9.21
Debt-to-Equity	3.07+0.8	2.31+0.6	1.67+0.3	1.35+0.2	1.15+0.1	1.05+0.0	1.01-0.2	1.24
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Pds Biotechnology Corporation PDSB

$35.4M

Polypid Ltd. PYPD

$83.8M

Vtv Therapeutics VTVT

$162.2M

Genenta Science Spa GNTA

$16.6M

Cue Biopharma Inc CUE

$17.6M

Frequently Asked Questions

What is Actinium Pharmac's annual revenue?

Actinium Pharmac (ATNM) reported $90K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Actinium Pharmac profitable?

No, Actinium Pharmac (ATNM) reported a net income of -$33.9M in fiscal year 2025, with a net profit margin of -37652.2%.

What is Actinium Pharmac's EBITDA?

Actinium Pharmac (ATNM) had EBITDA of -$36.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Actinium Pharmac's operating margin?

Actinium Pharmac (ATNM) had an operating margin of -40274.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Actinium Pharmac's net profit margin?

Actinium Pharmac (ATNM) had a net profit margin of -37652.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Actinium Pharmac's free cash flow?

Actinium Pharmac (ATNM) generated -$24.7M in free cash flow during fiscal year 2025. This represents a 25.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Actinium Pharmac's operating cash flow?

Actinium Pharmac (ATNM) generated -$24.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Actinium Pharmac's capital expenditures?

Actinium Pharmac (ATNM) invested $104K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Actinium Pharmac spend on research and development?

Actinium Pharmac (ATNM) invested $21.1M in research and development during fiscal year 2025.

How many shares does Actinium Pharmac have outstanding?

Actinium Pharmac (ATNM) had 31M shares outstanding as of fiscal year 2025.

Are Actinium Pharmac's earnings high quality?

Actinium Pharmac (ATNM) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.